NDAOPHTHALMICSOLUTION/DROPSPriority Review
Approved
Apr 2016
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
2/8 — Basic
Priority Review
PHOTREXA VISCOUS IN DEXTRAN 20% (riboflavin 5-phosphate ophthalmic) by Glaukos is 5'-phosphate sodium (vitamin b2) is the precursor of two coenzymes, flavin adenine dinucleotide and flavin mononucleotide, which catalyze oxidation/reduction reactions involved in a number of metabolic pathways. First approved in 2016.
Drug data last refreshed 21h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PHOTREXA VISCOUS IN DEXTRAN 20% is a riboflavin 5-phosphate ophthalmic solution approved by the FDA in April 2016 for corneal cross-linking procedures. It is used in conjunction with UV-A light exposure to strengthen corneal collagen and halt progressive keratoconus and corneal ectasia. The product works by enabling riboflavin-mediated photochemical cross-linking of corneal collagen fibers when activated by UVA light.
Peak
Product is in peak lifecycle stage with moderate competitive pressure (30%), indicating stable team size and established commercial infrastructure.
Mechanism of Action
5'-phosphate sodium (Vitamin B2) is the precursor of two coenzymes, flavin adenine dinucleotide and flavin mononucleotide, which catalyze oxidation/reduction reactions involved in a number of metabolic pathways. Under the conditions used for corneal collagen cross-linking, riboflavin 5'-phosphate…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on PHOTREXA VISCOUS offers exposure to specialized ophthalmology and procedural medicine with a niche but growing patient population. Career progression opportunities exist in peak-stage commercial optimization, though limited trial activity indicates focus on market consolidation rather than pipeline expansion.
Brand Manager
Worked on PHOTREXA VISCOUS IN DEXTRAN 20% at Glaukos? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.